


## Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies

Wisit Cheungpasitporn, Charat Thongprayoon, Wonngarm Kittanamongkolchai, Narat Srivali, Peter J. Edmonds, Patompong Ungprasert, Oisín A. O'Corragain, Sira Korpaisarn & Stephen B. Erickson


To cite this article: Wisit Cheungpasitporn, Charat Thongprayoon, Wonngarm Kittanamongkolchai, Narat Srivali, Peter J. Edmonds, Patompong Ungprasert, Oisín A. O'Corragain, Sira Korpaisarn & Stephen B. Erickson (2015) Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies, *Renal Failure*, 37:7, 1237-1241, DOI: [10.3109/0886022X.2015.1057800](https://doi.org/10.3109/0886022X.2015.1057800)


To link to this article: <http://dx.doi.org/10.3109/0886022X.2015.1057800>

 View supplementary material [↗](#)

 Published online: 25 Jun 2015.

 Submit your article to this journal [↗](#)

 Article views: 258

 View related articles [↗](#)

 View Crossmark data [↗](#)

 Citing articles: 1 View citing articles [↗](#)

## BRIEF REPORT

**Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies**Wisit Cheungpasitporn<sup>1</sup>, Charat Thongprayoon<sup>1</sup>, Wonngarm Kittanamongkolchai<sup>1</sup>, Narat Srivali<sup>2</sup>, Peter J. Edmonds<sup>3</sup>, Patompong Ungprasert<sup>4</sup>, Oisín A. O'Corragain<sup>5</sup>, Sira Korpaisarn<sup>6</sup>, and Stephen B. Erickson<sup>1</sup><sup>1</sup>Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA, <sup>2</sup>Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA, <sup>3</sup>Department of Medicine, SUNY Upstate Medical University, Syracuse, NY, USA, <sup>4</sup>Division of Rheumatology, Mayo Clinic, Rochester, MN, USA, <sup>5</sup>Department of Medicine, University College Cork, Cork, Ireland, and <sup>6</sup>Department of Medicine, MetroWest Medical Center, Framingham, MA, USA**Abstract**

**Background:** The reported risk of hypomagnesemia in patients with proton pump inhibitor (PPI) use is conflicting. The objective of this meta-analysis was to assess the association between the use of PPIs and the risk of hypomagnesemia. **Methods:** A literature search of observational studies was performed using MEDLINE, EMBASE and Cochrane Database of Systematic Reviews from inception through September 2014. Studies that reported odd ratios or hazard ratios comparing the risk of hypomagnesemia in patients with PPI use were included. Pooled risk ratios (RRs) and 95% confidence interval (CI) were calculated using a random-effect, generic inverse variance method. **Results:** Nine observational studies (three cohort studies, five cross-sectional studies and a case-control study) with a total of 109,798 patients were identified and included in the data analysis. The pooled RR of hypomagnesemia in patients with PPI use was 1.43 (95% CI, 1.08–1.88). The association between the use of PPIs and hypomagnesemia remained significant after the sensitivity analysis including only studies with high quality score (Newcastle–Ottawa scale score  $\geq 8$ ) with a pooled RR of 1.63 (95% CI, 1.14–2.23). **Conclusions:** Our study demonstrates a statistically significant increased risk of hypomagnesemia in patients with PPI use. The finding of this meta-analysis of observational studies suggests that PPI use is associated with hypomagnesemia and may impact clinical management of patients who are taking PPIs and at risk for hypomagnesemia related cardiovascular events.

**Keywords**

Electrolyte, hypomagnesemia, magnesium, meta-analysis, proton pump inhibitors

**History**

Received 1 February 2015

Revised 22 March 2015

Accepted 13 May 2015

Published online 25 June 2015

**Introduction**

Hypomagnesemia is a common clinical problem with a prevalence of  $\sim 10\%$  in hospitalized patients and up to 65% in critically ill patients.<sup>1</sup> The clinical consequences of severe hypomagnesemia include muscle weakness, tetany, convulsions, cardiac arrhythmias and hypotension.<sup>2–5</sup> Studies have also demonstrated an association between hypomagnesemia and both cardiovascular and non-cardiovascular mortality.<sup>6,7</sup> Magnesium (Mg) has been found to lower inflammation, decrease oxidative stress and diminish endothelial dysfunction – all factors that underlie cardiovascular disease. Further, magnesium helps to reduce platelet aggregation, which could help to prevent the formation of dangerous blood clots.<sup>8</sup> Serious arrhythmias and sudden death have been reported in patients with hypomagnesemia and cardiovascular disease. Several prospective epidemiological studies have also shown

a relationship between hypomagnesemia and the risk of recurrent coronary heart disease.<sup>9,10</sup> Moreover, hypomagnesemia was demonstrated to be associated with nonrecovery of renal function after acute kidney injury episodes.<sup>11</sup>

Proton pump inhibitors (PPIs) are commonly used worldwide, with or without a prescription, for the treatment of acid-related disorders. In the United States, PPIs have been increasingly prescribed; over 100 million times a year for the past five years.<sup>5</sup> Studies, however, have reported the adverse effects of PPIs including the risk of acute interstitial nephritis,<sup>12</sup> *Clostridium difficile* colitis,<sup>13</sup> hospital-acquired pneumonia<sup>14</sup> and hip fractures.<sup>15</sup> Recently, severe hypomagnesemia has been described in more than 30 cases with PPI therapy in a systematic review.<sup>16</sup> Regarding this potential adverse effect, the US Food and Drug Administration (FDA) issued a warning that PPIs may reduce Mg levels in March 2011.<sup>17</sup> However, studies have subsequently demonstrated conflicting results on PPI use and the risk of hypomagnesemia. Several studies have shown that hypomagnesemia is associated with the use of PPIs.<sup>18–21</sup> Conversely, a number of studies have demonstrated no associations between PPI use and hypomagnesemia.<sup>5,22–24</sup>

Address correspondence to Wisit Cheungpasitporn, MD, Department of Medicine, Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA. Tel: + 1 507 266 7960; Fax: + 1 507 266 7891; E-mail: wcheungpasitporn@gmail.com

The objective of this meta-analysis was to assess the association between the use of PPIs and the risk of hypomagnesemia.

## Methods

### Search strategy

Two investigators (WC and CT) independently searched published studies indexed in MEDLINE, EMBASE and the Cochrane database from inception through September 2014 using the search strategy described in online Supplementary Material. A manual search for additional relevant studies using references from retrieved articles was also performed.

### Inclusion criteria

The inclusion criteria were as follows: (1) observational studies (cohort studies, case-control or cross-sectional) published as original studies or conference abstracts to evaluate the risk of hypomagnesemia in patients with PPI use, (2) odds ratios, relative risks or hazard ratios with 95% confidence intervals (CIs) were presented and (3) a reference group composed of participants who did not use PPIs.

Study eligibility was independently determined by the two investigators noted above. Differing decisions were resolved by mutual consensus. The quality of each study was independently assessed by each individual investigator using the Newcastle–Ottawa quality assessment scale.<sup>25</sup>

### Data extraction

A standardized data collection form was used to extract the following information: last name of the first author, study design, year of study, country of origin, year of publication, sample size, characteristics of included participants, definition of PPI use, method used to diagnose hypomagnesemia and adjusted effect estimates with 95% CI. The two investigators independently performed this data extraction.

### Statistical analysis

Review Manager 5.2 software (Copenhagen, Denmark) from the Cochrane Collaboration was used for data analysis. Point estimates and standard errors were extracted from individual studies and were combined by the generic inverse variance method of DerSimonian and Laird.<sup>26</sup> Given the high likelihood of between study variances, we used a random-effect model rather than a fixed-effect model. Statistical heterogeneity was assessed using the Cochran's  $Q$  test. This statistic is complemented with the  $I^2$  statistic, which quantifies the proportion of the total variation across studies that is due to heterogeneity rather than chance. A value of  $I^2$  of 0–25% represents insignificant heterogeneity, 26–50% low heterogeneity, 51–75% moderate heterogeneity and >75% high heterogeneity.<sup>27</sup> The presence of publication bias was assessed by funnel plots of the logarithm of odds ratios versus their standard errors.<sup>28</sup>

## Results

Our search strategy yielded 681 potentially relevant articles. Six hundred and sixty articles were excluded based on title

and abstract for certainly not fulfilling inclusion criteria on the basis of the type of article, study design, population or outcome of interest. Twenty-one articles underwent full-length article review. Twelve articles were excluded (seven articles were not observational studies and five articles did not report the outcomes of interest). Nine observational studies with a total of 109,798 patients were identified and included in the data analysis. Our search methodology and selection process were included in online Supplementary Material.

### The risk of hypomagnesemia in patients with PPI use

Nine observational studies<sup>5,18–24,29</sup> (three cohort studies, five cross-sectional study and a case control study) with a total of 109,798 patients were included in the data analysis for the risk of hypomagnesemia in patients with PPI use. Table 1 describes the detailed characteristics and quality assessment of the included studies. The pooled RR of hypomagnesemia in patients with PPI use was 1.43 (95% CI, 1.08–1.88,  $I^2$  of 87%). Figure 1 shows the forest plot of the included studies. The association between the use of PPIs and hypomagnesemia remained significant after the sensitivity analysis including only studies with high quality scores (Newcastle–Ottawa scale score  $\geq 8$ ) with a pooled RR of 1.63 (95% CI, 1.14–2.23,  $I^2$  of 91%).

### Evaluation for publication bias

A funnel plot to evaluate publication bias for the risk of hypomagnesemia in patients with PPI use is summarized in Figure 2. The plot did not show significant publication bias of included studies.

## Discussion

Our meta-analysis results indicate a significant association between hypomagnesemia and the use of PPIs with an overall 1.43-fold increased risk of hypomagnesemia compared to those who did not use PPIs. This association remains significant with the sensitivity analysis including only high-quality studies (Newcastle–Ottawa scale score  $\geq 8$ ) with a 1.63-fold increased risk of hypomagnesemia.

The findings of our meta-analysis confirmed the FDA's warning of PPI-related hypomagnesemia. The underlying mechanism of the association of hypomagnesemia in patients with PPI use is likely explained by the disturbance of gastrointestinal (GI) handling of Mg since studies have shown that an increased renal Mg loss is not the only culprit in those patients with significant hypomagnesemia after PPI use.<sup>30</sup> Although, GI absorption of Mg occurs by passive movement between enterocytes, it is augmented by an active transport system utilizing transient receptor potential Melastatin 6 (TRMP6) and TRPM7. A decrease in intestinal luminal pH by the use of PPIs may alter TRPM6/TRPM7 channel affinity for Mg and disrupt the active transport system. The passive paracellular Mg absorption across the GI tract, however, is not affected by alteration of pH by PPIs. Therefore, hypomagnesemia does not occur in everyone who uses PPIs due to sufficient passive GI absorption of Mg. The risk of PPI-induced hypomagnesemia should be considered in patients

Table 1. Main characteristics of the studies included in this meta-analysis.

	Gau et al. <sup>18</sup>	Koulouridis et al. <sup>24</sup>	Kim et al. <sup>19</sup>	Faulhaber et al. <sup>29</sup>	Danziger et al. <sup>5</sup>
Country	USA	USA	Korea	Brazil	USA
Study design	Cross-sectional study	Case-control study	Cohort study	Cross-sectional study	Cross-sectional study
Year	2012	2013	2013	2013	2013
Total number	487	804 (402 cases and 402 age- and sex-matched control)	112	151	11,490
Study sample	Hospitalized patients; aged $\geq 50$ years	Hospitalized patients with ICD-9 diagnosis code for disorders of esophagus, stomach and duodenum	Patients who were treated with PPI $\geq 30$ days; aged $\geq 20$ years	Hospitalized patients with acute disease in internal medicine division without the conditions that are commonly associated with hypomagnesemia	Adult patients who were admitted to surgical and medical ICUs
Exposure definition	PPI use	Out-of-hospital PPI	Duration of PPI use over 1 year	PPI use	Any PPI listed as preadmission medication
Exposure measurement	Medical record review	Medical record review	Medical record review	Medical record review	Medical record review using Natural Language Processing algorithm
Outcome definition	Magnesium levels $< 1.7$ mg/dL	Magnesium level $< 1.7$ mg/dL	Magnesium levels $< 1.7$ mg/dL	Not defined	Magnesium level $< 1.6$ mg/dL
Outcome ascertainment	The first serum magnesium level measured during admission	Magnesium at the time of hospital admission or the next day	Serum magnesium levels were collected and categorized as pre-PPI treatment levels, during PPI treatment levels, and post-PPI treatment levels	Magnesium measured in hospital	The first magnesium level recorded within 36 hours of admission to hospital
Adjusted OR or relative risk	2.50 (1.43–4.36)	0.82 (0.61–1.11)	5.39 (1.06–27.49)	n/a*	1.10 (0.96–1.25) In diuretic user 1.54 (1.22–1.95) In non-diuretic user 0.92 (0.78–1.09)
Confounder adjusted	Age, sex, diabetes mellitus, congestive heart failure, diuretics use, supplementation of potassium and magnesium, discharge diagnosis of any acute GI illness, serum albumin, potassium and creatinine	Charlson/Deyo comorbidity index, diabetes mellitus, GERD, use of diuretics and eGFR	Other electrolytes, laboratory Data, such as sodium, potassium, calcium, blood urea nitrogen, creatinine, albumin, age, gender, comorbidities and the use of other medications	None	Age, gender, ethnicity, renal function, systolic blood pressure, heart rate, temperature, serum calcium, phosphate, glucose, hematoctrit, diuretic use and 30 comorbidities
Quality assessment (Newcastle–Ottawa scale)	Selection: 3 Comparability: 2 Outcome: 3	Selection: 2 Comparability: 2 Exposure: 3	Selection: 3 Comparability: 2 Outcome: 3	Selection: 2 Comparability: 0 Outcome: 3	Selection: 4 Comparability: 2 Outcome: 3

Note: eGFR, estimated glomerular filtration rate; GERD, gastroesophageal reflux disease; GI, gastrointestinal; ICD, the international classification of diseases; ICUs, intensive care units; PPIs, proton pump inhibitors.

\*No hypomagnesemia occurred in both groups.





Figure 1. Forest plot of the included studies comparing risk of hypomagnesemia in patients who used PPI and those who did not; square data markers represent risk ratios (RRs); horizontal lines, the 95% CIs with marker size reflecting the statistical weight of the study using random-effects meta-analysis. A diamond data marker represents the overall RR and 95% CI for the outcome of interest. IV, inverse variance; SE, standard error.

Figure 2. Funnel plot of nine studies included in the meta-analysis for the risk of hypomagnesemia in patients with PPI use. The plot did not show significant publication bias of included studies. RR = risk ratio, SE = standard error.



with a low intake of Mg, GI malabsorption disorders or an increased renal loss of Mg due to diuretic use.

Although, almost all included studies were of moderate to high quality (as evaluated by Newcastle–Ottawa scale) and we also confirmed the result by sensitivity analysis in only high quality studies,<sup>5,18,20,24</sup> there are some limitations. Firstly, there are statistical heterogeneities in the complete analysis. The potential sources of these heterogeneities include the differences in the exposure definition (types of PPI and duration of PPI use), the differences in confounder adjusted methods and the duration of the follow-up, and the different patient settings (inpatient and outpatient). Unfortunately, the data on types of PPI and duration of PPI use in the included studies of our meta-analysis are limited, so we were unable to investigate these details, and further studies are needed. In addition, although most of the included studies adjusted for diuretic use, GI malabsorption and malnutrition are also very important factors that need to take into consideration. Lastly, this is a meta-analysis of observational studies with its

inherent limitations. Therefore, our meta-analysis can at best demonstrate an association but not a causal relationship. However, since epidemiological studies have shown the association between hypomagnesemia and the risk of recurrent coronary heart disease and serious arrhythmias,<sup>9,10</sup> PPIs need to be cautiously used in patients with cardiovascular diseases and hypomagnesemia.

In conclusion, our study suggests a statistically significant association between PPI use and hypomagnesemia. Physicians should be aware of this potential association which may impact clinical management of patients who are taking PPIs who are at risk for cardiovascular events from hypomagnesemia, especially those who have impairment in gastrointestinal absorptive capacity for magnesium, renal losses of magnesium due to diuretics or poor nutrition.

#### Acknowledgments

All authors had access to the data and a role in writing the manuscript.



## Declaration of interest

We wish to confirm that all authors have no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

## References

1. Agus ZS. Hypomagnesemia. *J Am Soc Nephrol.* 1999;10:1616–1622.
2. Moore MJ, Flink EB. Magnesium deficiency as a cause of serious arrhythmias. *Arch Intern Med.* 1978;138:825–826.
3. Vallee BL, Wacker WE, Ulmer DD. The magnesium-deficiency tetany syndrome in man. *N Engl J Med.* 1960;262:155–161.
4. Flink EB. Magnesium deficiency. Etiology and clinical spectrum. *Acta Med Scand Suppl.* 1981;647:125–137.
5. Danziger J, William JH, Scott DJ, et al. Proton-pump inhibitor use is associated with low serum magnesium concentrations. *Kidney Int.* 2013;83:692–699.
6. Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Isaka Y. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. *Kidney Int.* 2014;85:174–181.
7. Reffelmann T, Ittermann T, Dorr M, et al. Low serum magnesium concentrations predict cardiovascular and all-cause mortality. *Atherosclerosis.* 2011;219:280–284.
8. Bo S, Pisu E. Role of dietary magnesium in cardiovascular disease prevention, insulin sensitivity and diabetes. *Curr Opin Lipidol.* 2008;19:50–56.
9. Liao F, Folsom AR, Brancati FL. Is low magnesium concentration a risk factor for coronary heart disease? The atherosclerosis risk in communities (Aric) study. *Am Heart J.* 1998;136:480–490.
10. Del Gobbo LC, Imamura F, Wu JH, de Oliveira Otto MC, Chiuve SE, Mozaffarian D. Circulating and dietary magnesium and risk of cardiovascular disease: A systematic review and meta-analysis of prospective studies. *Am J Clin Nutr.* 2013;98:160–173.
11. Alves SC, Tomasi CD, Constantino L, et al. Hypomagnesemia as a risk factor for the non-recovery of the renal function in critically ill patients with acute kidney injury. *Nephrol Dial Transplant.* 2013;28:910–916.
12. Sierra F, Suarez M, Rey M, Vela MF. Systematic review: Proton pump inhibitor-associated acute interstitial nephritis. *Aliment Pharmacol Ther.* 2007;26:545–553.
13. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial clostridium difficile infection. *Arch Intern Med.* 2010;170:784–790.
14. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. *JAMA.* 2009;301:2120–2128.
15. Yu EW, Bauer SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: A meta-analysis of 11 international studies. *Am J Med.* 2011;124:519–526.
16. Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: Hypomagnesaemia induced by proton pump inhibition. *Aliment Pharmacol Ther.* 2012;36:405–413.
17. US Department of Health and Human Services F DSC. Drug safety communication—Low magnesium levels can be associated with long-term use. Available from: <http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm>. Accessed March 3, 2011.
18. Gau JT, Yang YX, Chen R, Kao TC. Uses of proton pump inhibitors and hypomagnesemia. *Pharmacoeconom Drug Saf.* 2012;21:553–559.
19. Kim S, Lee H, Park CH, et al. Clinical predictors associated with proton pump inhibitor-induced hypomagnesemia. *Am J Ther.* 2015;22:14–21.
20. Markovits N, Loebstein R, Halkin H, et al. The association of proton pump inhibitors and hypomagnesemia in the community setting. *J Clin Pharmacol.* 2014;54:889–895.
21. Smith K, Gatesman ML, Harpe SE, Clark W. Evaluation of electrolyte repletion in hematopoietic cell transplant patients receiving h-2 receptor antagonists or proton pump inhibitors. *Bone Marrow Transplant.* 2014;49:1106–1108.
22. El-Charabaty E, Saifan C, Abdallah M, et al. Effects of proton pump inhibitors and electrolyte disturbances on arrhythmias. *Int J Gen Med.* 2013;6:515–518.
23. Gil HW PS, Hong SY. Change in serum magnesium concentration after use of a proton pump inhibitor. *51st ERA-EDTA Congress, Amsterdam, Netherlands: Oxford University Press; 2014;29:iii180–iii181.*
24. Koulouridis I, Alfayez M, Tighiouart H, et al. Out-of-hospital use of proton pump inhibitors and hypomagnesemia at hospital admission: A nested case-control study. *Am J Kidney Dis.* 2013;62:730–737.
25. Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol.* 2010;25:603–605.
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials.* 1986;7:177–188.
27. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ.* 2003;327:557–560.
28. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. *Lancet.* 1991;337:867–872.
29. Faulhaber GA, Ascoli BM, Lubini A, et al. Serum magnesium and proton-pump inhibitors use: A cross-sectional study. *Rev Assoc Med Bras.* 2013;59:276–279.
30. Perazella MA. Proton pump inhibitors and hypomagnesemia. A rare but serious complication. *Kidney Int.* 2013;83:553–556.

Supplementary material available online